Key Highlights

  • Qiagen (NYSE:QGEN) agreed on Wednesday, October 21, 2026 to a recommended all-cash offer from EQT at EUR 46.50 per share, about a 40% premium, worth about USD 12.1 billion including debt.
  • Roivant Sciences (NASDAQ:ROIV) jumped after brepocitinib met the primary endpoint in two Phase 3 uveitis trials, with 62% of patients in steroid-free control at week 48 against 20% on placebo.
  • Thermo Fisher Scientific (NYSE:TMO) beat revenue estimates by about USD 200 million at USD 12.14 billion, raised 2026 revenue guidance to USD 47.7 billion to USD 48.2 billion and closed about 4% higher.
  • All three moved with US 10-year yields near 5.1%, a level that raises the cost of buyout debt and biotechnology funding, yet capital still went to cash flow, clean data and steady demand.

Qiagen (NYSE:QGEN): a take-private at about a 40% premium

Qiagen (NYSE:QGEN), a Netherlands-based supplier of molecular testing products used to prepare samples and detect diseases such as tuberculosis, agreed on Wednesday, October 21, 2026 to a recommended voluntary all-cash public takeover offer from private equity firm EQT. The bidding vehicle, backed by the EQT XI fund, offers EUR 46.50 per share, about a 40% premium. That implies an equity value of about EUR 9.6 billion, or about USD 10.8 billion, and about USD 12.1 billion including debt. Abu Dhabi Investment Authority and CPP Investments, the Canadian pension fund manager, are co-investors, and closing is targeted for mid-2027.

The offer replaces an uncertain market value with a fixed cash price, subject to completion. A private equity buyer typically funds such a deal with fund equity and borrowed money, then seeks to raise cash flow before selling or relisting years later, and co-investors reduce the equity cheque EQT must write from its own fund. The gap between about USD 10.8 billion of equity and about USD 12.1 billion of enterprise value reflects net debt the buyer assumes. Because the price is fixed in euros, the merger arbitrage spread on the US-listed shares prices currency exposure, the time to mid-2027 and completion risk.

The first risk is completion, since the offer needs regulatory clearances and enough shareholder acceptances. The second is financing cost, with 10-year yields near 5.1% raising the price of leveraged debt, and the third is a weaker euro, which would cut the dollar value of the offer. Analysts at Oddo BHF cut their price target for EQT to SEK 370 after the announcement, a reminder that the buyer also carries risk. Qiagen shares had risen about 2% as reports of an imminent deal circulated.

Roivant Sciences (NASDAQ:ROIV): two Phase 3 wins in uveitis

Roivant Sciences (NASDAQ:ROIV), a biopharmaceutical group that develops drugs through subsidiaries, jumped on Wednesday, October 21, 2026 after its subsidiary Priovant reported results from CLARITY-1 and CLARITY-2. The identical Phase 3 trials enrolled 166 and 204 patients with non-infectious uveitis, an inflammatory eye disease, who took brepocitinib 45 mg or placebo once daily for 48 weeks after an eight-week steroid taper. Hazard ratios of 0.27 and 0.22 meant the risk of treatment failure was about 73% to 78% lower than on placebo, with p-values below 0.0001. In pooled data, 62% of treated patients reached steroid-free control at week 48, against 20% on placebo.

The steroid-free result carries the commercial case. Uveitis of this kind affects an estimated 70,000 to 190,000 US adults, and doctors typically control flares with corticosteroids, which cause cataracts, glaucoma and bone loss with long use. Brepocitinib blocks TYK2 and JAK1, two enzymes that relay inflammatory signals, and is already approved as LISRAYA for dermatomyositis, so a supplemental filing planned for the first half of 2027 can draw on an existing safety record. Unlike the Qiagen offer, the value here rests on data rather than an agreed price, so it stays exposed to review.

The first risk is regulatory, since the JAK inhibitor class carries safety warnings in the US. The second is uptake, given the wide patient estimate and the need for rheumatologists and eye specialists to change established prescribing habits, and the third is timing, as a 2027 filing pushes uveitis revenue further out. The share price now discounts more success, which raises the cost of any setback in other programmes. The investor day on Wednesday, December 9, 2026 is the next company event.

Thermo Fisher Scientific (NYSE:TMO): steady demand from drugmakers

Thermo Fisher Scientific (NYSE:TMO), the largest supplier of laboratory instruments, consumables and outsourced drug development and manufacturing services, reported third-quarter results on Wednesday, October 21, 2026. Revenue rose 9% to USD 12.14 billion, about USD 200 million above consensus estimates, and organic growth was 6%. Adjusted EPS rose 15%, and operating margins expanded. The company raised its 2026 revenue guidance to USD 47.7 billion to USD 48.2 billion, a midpoint of about USD 47.95 billion. The shares dipped early in the session, then reversed to close about 4% higher.

Revenue up 9% produced adjusted EPS up 15%, a spread of about six percentage points that came from operating leverage, the way profit grows faster than revenue once fixed costs are covered. Organic growth of 6% shows demand from existing customers, such as drugmakers buying bioprocessing materials and laboratories buying consumables, and that recurring stream is more predictable than instrument sales. Thermo Fisher sits on the spending side of the same theme, selling to the drug developers whose trials and production create value at companies such as Roivant.

The first risk is that 6% organic growth reflects the timing of orders rather than a lasting recovery, particularly in bioprocessing, where customers adjust inventory levels. The second is funding for academic and government research, which could shift after the midterm elections. The third is rates: the federal funds range of 3.75% to 4.00% raises funding costs for biotechnology customers and weighs on long-duration valuations. Margins also depend on keeping cost growth below sales growth.

Where Things Stand

The answer is that capital still paid for life science assets with visible cash flow or clean data, even with 10-year yields near 5.1%. EQT and its co-investors offered about a 40% premium for the molecular testing business of Qiagen (NYSE:QGEN), accepting higher financing costs and a mid-2027 close. Roivant Sciences (NASDAQ:ROIV) was rerated on two Phase 3 wins, with 62% steroid-free control against 20%, while Thermo Fisher Scientific (NYSE:TMO) showed that demand from drugmakers and laboratories supported 6% organic growth and a higher revenue range. The next catalysts are the Fed decision on Wednesday, October 28, 2026, the midterm elections on Tuesday, November 3, 2026, the Qiagen offer document and the Roivant investor day on December 9. Deal terms, trial results and guidance are not guarantees, and this is not investment advice.